Patent · US Active

Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis

US9603890B2 · kind B2 · utility

2Cited by
3References
2Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 3, 2013
Grant dateMar 28, 2017
Priority date—
Expiry dateDec 3, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/321
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.